What Tesamorelin is
Tesamorelin is a GHRH analog that stimulates endogenous growth hormone release and is used in a specific approved metabolic context.
Tesamorelin is grouped under Fitness + Recovery / Approved / Clinical on PeptideFactCheck because it is one of the few GH-axis peptides with an official drug-label pathway, making it a useful contrast to research peptides.
The useful starting point is to separate the molecule itself from the internet story around it. It is one of the rare GH-axis peptides with an official clinical label.
Why people keep looking it up
People connect tesamorelin with visceral-fat reduction and GH-axis medicine.
Tesamorelin stimulates GHRH signaling, which can increase endogenous growth hormone release in a specific approved context.
Tesamorelin tends to stay in the conversation because it touches a familiar public theme: ghrh analog, visceral fat, and gh axis. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Approved use is specific. Internet body-composition claims still need to stay separate from the label.
Human clinical evidence and labeling support specific approved use, while off-label optimization claims require separate evaluation.
Mechanistic rationale follows GHRH receptor activation and downstream GH/IGF-1 signaling.
Why this page carries the current tier: Approved status for a specific use with official labeling and human trials.
The current seed trail for Tesamorelin is pulling from 1 labels source, 1 regulatory source, and 1 literature source.
Safety, limits, and regulatory context
Risk assessment should follow official labeling and clinician supervision for approved contexts.
FDA-approved drug labeling exists for tesamorelin products. PeptideFactCheck treats labeled use separately from internet extrapolations.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Tesamorelin. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Tesamorelin is CID 16137828. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 16137828
- Formula
- C221H366N72O67S
- Molecular weight
- 5136
- InChIKey
- QBEPNUQJQWDYKU-BMGKTWPMSA-N
Matched synonyms include Tesamorelin, TH9507, MQG94M5EEO, 218949-48-5, DTXSID00583207, TH 9507, tesamorelina, tesamoreline.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Tesamorelin returns 24 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Tesamorelin returns 118 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
- Brand names
- EGRIFTA SV
- Generic names
- TESAMORELIN
- Routes
- SUBCUTANEOUS
- Application numbers
- BLA022505
Indications and usage. 1 INDICATIONS AND USAGE EGRIFTA SV is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. Limitations of Use: Long-term cardiovascular safety of EGRIFTA SV has not been established. Consider risk/benefit of continuation of treatment in patients who have not had a reduction in visceral adipose tissue. EGRIFTA SV is not indicated for weight loss management as it has a...
Warnings and cautions. 5 WARNINGS AND PRECAUTIONS Increased risk of neoplasms: Preexisting malignancy should be inactive and its treatment complete prior to starting EGRIFTA SV . Discontinue EGRIFTA SV if there is any evidence of recurrent malignancy. ( 5.1 ) Elevated IGF-1: EGRIFTA SV stimulates GH production and increases serum IGF-1, a growth factor. The effects of prolonged elevations in IGF-1 levels are unknown. Monitor IGF-1 levels...
Contraindications. 4 CONTRAINDICATIONS EGRIFTA SV is contraindicated in: Patients with disruption of the hypothalamic-pituitary axis ( 4 ) Patients with active malignancy ( 4 ) Patients with known hypersensitivity to tesamorelin or excipients in EGRIFTA SV ( 4 ) Pregnancy ( 4 ) EGRIFTA SV is contraindicated in: Patients with disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumor/surgery,...
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.